Table 1.
Trial schedule
| Assessment | Period | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| (Date of onset) | Registration | Start date of observation | 1 M | 3 M | 6 M | 12 M | Thereafter, every 6 months | Completion of observation (*) | |
| Informed consent |  |
○ | |||||||
| Demographics |  |
○ | |||||||
| Modified Rankin Scale (mRS) | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ||
| Compliance status of trial drugs | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ||
| Concomitant medication | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ||
| Blood pressure | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ||
| Head MRI |  |
○ | |||||||
| Head MRA, T2*WI |  |
△ |  |
||||||
| Carotid artery imaging (US, CTA, MRA) |  |
△ |  |
||||||
| Laboratory test (blood) |  |
○ |  |
||||||
| Laboratory test (urine) |  |
○ |  |
||||||
| Chest X-ray |  |
○ |  |
||||||
| ECG |  |
○ |  |
||||||
| Adverse event |  |
||||||||
*
When patients are withdrawn from the trial, or one-year after the start of the protocol treatment in the last patient.
○, required; △, optional.